Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P-CD19CD20-ALLO1 in Relapsed/Refractory B Cell Malignancies
NCT06014762Phase 1Active, not recruiting
- Sponsor
- Poseida Therapeutics
- Start
- Apr 2024
- Primary completion
- Mar 2029
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of P-CD19CD20-ALLO1 in diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and 2 more (3 arms), sponsored by Poseida Therapeutics. Primary endpoint: Dose Limiting Toxicities at 28 days. Started Apr 2024; status: active, not recruiting.
02
Drugs
P-CD19CD20-ALLO1
03
Conditions
diffuse large B-cell lymphoma (DLBCL)high grade B-cell lymphoma (HGBCL)primary mediastinal large B-cell lymphoma (PMBCL)Transformed Follicular Lymphoma (tFL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT06014762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06014762.